We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.5M
AUM Growth
+$26M
Cap. Flow
+$35.8M
Cap. Flow %
37.05%
Top 10 Hldgs %
76.97%
Holding
60
New
14
Increased
12
Reduced
2
Closed
28

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$12.8M
2
VTRS icon
Viatris
VTRS
+$6.56M
3
CELG
Celgene Corp
CELG
+$5.66M
4
AGN
Allergan plc
AGN
+$5.24M
5
SNY icon
Sanofi
SNY
+$4.7M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$5.49M
2
ABBV icon
AbbVie
ABBV
+$3.64M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.84M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$1.98M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$807K

Sector Composition

Rank Sector Weight
1 Healthcare 89.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
51
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-33,333
Closed -$444K
AAAP
52
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-7,500
Closed -$235K
SCLN
53
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
– –
-65,000
Closed -$598K
MACK
54
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-4,576
Closed -$284K
TLOG
55
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
– –
-64,000
Closed -$111K
VTAE
56
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-20,720
Closed -$375K
CPXX
57
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-90,000
Closed -$158K
CTIC
58
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-65,600
Closed -$807K
GNVC
59
DELISTED
GenVec, Inc.
GNVC
– –
-1,910
Closed -$35K
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Nexthera Capital held 60 positions worth $96.5M, up 37% from $70.5M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Nexthera Capital deployed $35.8M of net new capital in Q1 2016, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Shire pic: 76,200 shares worth $13.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $2.84M trimmed.

  • Nexthera Capital's largest Q1 2016 buy was Shire pic: 76,200 shares worth $13.1M.
  • Nexthera Capital added most to Celgene Corp in Q1 2016, an estimated $5.66M increase.
  • Nexthera Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $2.84M.
  • Nexthera Capital fully exited Merck in Q1 2016, selling an estimated $5.49M.
  • Nexthera Capital's ten largest holdings make up 77% of its $96.5M portfolio in Q1 2016.
  • Nexthera Capital opened 14 new positions and closed 28 in Q1 2016.
  • Nexthera Capital's portfolio value rose 37% quarter-over-quarter to $96.5M.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.